Equities analysts forecast that Chimerix Inc (NASDAQ:CMRX) will announce ($0.49) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Chimerix’s earnings, with the highest EPS estimate coming in at ($0.43) and the lowest estimate coming in at ($0.56). Chimerix reported earnings per share of ($0.32) in the same quarter last year, which would indicate a negative year-over-year growth rate of 53.1%. The business is scheduled to announce its next earnings results on Thursday, March 1st.
According to Zacks, analysts expect that Chimerix will report full-year earnings of ($1.60) per share for the current fiscal year, with EPS estimates ranging from ($1.64) to ($1.56). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.89) per share, with EPS estimates ranging from ($2.12) to ($1.70). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that follow Chimerix.
Chimerix (NASDAQ:CMRX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. The company had revenue of $0.90 million during the quarter, compared to analyst estimates of $0.81 million. Chimerix had a negative return on equity of 26.00% and a negative net margin of 1,440.67%.
A number of research firms have weighed in on CMRX. ValuEngine upgraded Chimerix from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 11th. Zacks Investment Research lowered Chimerix from a “hold” rating to a “sell” rating in a report on Monday, January 22nd. Finally, HC Wainwright began coverage on Chimerix in a report on Friday. They set a “buy” rating and a $10.00 target price for the company. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $7.06.
Shares of Chimerix (CMRX) opened at $4.70 on Friday. The firm has a market capitalization of $221.50, a price-to-earnings ratio of -3.29 and a beta of 1.42. Chimerix has a twelve month low of $4.17 and a twelve month high of $6.64.
In other news, insider Linda M. Richardson sold 19,833 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $4.47, for a total transaction of $88,653.51. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 4.40% of the company’s stock.
Several hedge funds have recently modified their holdings of CMRX. Voya Investment Management LLC increased its position in shares of Chimerix by 18.3% during the second quarter. Voya Investment Management LLC now owns 29,203 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 4,526 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Chimerix by 8.3% during the second quarter. The Manufacturers Life Insurance Company now owns 39,628 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 3,042 shares in the last quarter. Rhumbline Advisers increased its position in shares of Chimerix by 7.3% during the second quarter. Rhumbline Advisers now owns 48,541 shares of the biopharmaceutical company’s stock worth $265,000 after purchasing an additional 3,300 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Chimerix during the fourth quarter worth $280,000. Finally, Nationwide Fund Advisors increased its position in shares of Chimerix by 70.3% during the third quarter. Nationwide Fund Advisors now owns 60,567 shares of the biopharmaceutical company’s stock worth $318,000 after purchasing an additional 24,994 shares in the last quarter. 70.40% of the stock is currently owned by institutional investors and hedge funds.
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.